



Contra Costa Health Plan
P&T Formulary Update
September 3, 2020

Volume 15

Changes effective: 10/10/2020

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On September 3, 2020 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Potassium Binders • Ulcerative colitis, Crohn's Disease Agents • Bowel Prep Agents • Oral and Topical Antivirals	• Antitubercular Agents • Ophthalmic steroids • Chelating Agents
Drug Monographs	
• Nexletol (Bempedoic acid) • Nexlizet (Bempedoic acid-ezetimibe)	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Durezol (Difluprednate) • Rukovia (Fostemsavir) • Nexletol (Bempedoic acid) • Nexlizet (Bempedoic acid-ezetimibe) <u>Updates were made to the criteria for the following agents:</u> • Potassium Binders <u>Criteria reviewed and unchanged:</u> • Oral and Topical Antivirals • Antitubercular Agents • Ophthalmic steroids • Chelating Agents <u>The following drugs were added to the CCHP formulary:</u> • Lokelma (sodium zirconium cyclosilicate) • Veltassa (Patiromer) • Propranolol ER	

Budesonide EC	
Guest Speaker(s)	
None	
<u>CCHP P&T Committee approved the following modifications to the formulary:</u>	
Medication Name & Dosage Strength	Approved Formulary Changes
Durezol (Difluprednate)	Added to formulary, Tier 2 ST
Lokelma (sodium zirconium cyclosilicate)	Added to formulary, Tier 2 QL
Veltassa (Patiromer)	Added to formulary, Tier 2 ST
Propranolol ER	Added to formulary, Tier 1
Budesonide EC 3mg	Added to formulary, Tier 2 QL
New Product Reviews (including new indications)	
- Emerphed (Ephedrine IV) - Jelmyto (Mitomycin) solution - Halog (Halcinonide) topical solution - Dayvigo (Lemborexant) oral tablets - Nymalize (Nimodipine) syringe - Darzalex Faspro (Daratumumab) - Fensolvi (Leuprolide acetate) - Durysta (Bimatoprost) implant - Tabrecta (Capmatinib) tablets - Retevmo (Selpercatinib) capsules - Osmolex (Amantadine ER) tablet - Jynarque (Tolvaptan) tablet - Qinlock (Ripretinib) oral tablets - Zeposia (Ozanimod) capsules - Avsola (Infliximab-axxq) IV - Phexxi (Lactic acid/citric acid/potassium bitartrate) vaginal gel - Oriahnn (Elagolix/estradiol/norethindrone)	- Kynmobi (Apomorphine) sublingual - Zilxi (Minocycline) 1.5% topical foam - Tivicay PD (Dolutegravir) tablets - Lyumjev (Insulin lispro) SQ - Uplizna (Inebilizumab-cdon) IV - Zepzelca (Lurbinectedin) IV vial - Xpovio (Selinexor) oral tablets - Twirla (levonorgestrel/ethinyl estradiol) transdermal patch - Phesgo (pertuzumab-trastuzumab-hu-zzxf) subcutaneous solution - Fintepla (fenfluramine) oral solution - Dojolvi (triheptanoin) oral liquid - Ortikos (Budesonide) 6mg, 9mg capsule, extended release - Tasoprol (Clobetasol Prop/Gauze/Silicone) topical kit - Zolpack (Econazole) Transparent dressing topical kit